Review
GABAA receptors: structure, function, pharmacology, and related disorders

https://doi.org/10.1186/s43141-021-00224-0Get rights and content
Under a Creative Commons license
open access

Abstract

Background

γ-Aminobutyric acid sub-type A receptors (GABAARs) are the most prominent inhibitory neurotransmitter receptors in the CNS. They are a family of ligand-gated ion channel with significant physiological and therapeutic implications.

Main body

GABAARs are heteropentamers formed from a selection of 19 subunits: six α (alpha1-6), three β (beta1-3), three γ (gamma1-3), three ρ (rho1-3), and one each of the δ (delta), ε (epsilon), π (pi), and θ (theta) which result in the production of a considerable number of receptor isoforms. Each isoform exhibits distinct pharmacological and physiological properties. However, the majority of GABAARs are composed of two α subunits, two β subunits, and one γ subunit arranged as γ2β2α1β2α1 counterclockwise around the center. The mature receptor has a central chloride ion channel gated by GABA neurotransmitter and modulated by a variety of different drugs. Changes in GABA synthesis or release may have a significant effect on normal brain function. Furthermore, The molecular interactions and pharmacological effects caused by drugs are extremely complex. This is due to the structural heterogeneity of the receptors, and the existence of multiple allosteric binding sites as well as a wide range of ligands that can bind to them. Notably, dysfunction of the GABAergic system contributes to the development of several diseases. Therefore, understanding the relationship between GABAA receptor deficits and CNS disorders thus has a significant impact on the discovery of disease pathogenesis and drug development.

Conclusion

To date, few reviews have discussed GABAA receptors in detail. Accordingly, this review aims to summarize the current understanding of the structural, physiological, and pharmacological properties of GABAARs, as well as shedding light on the most common associated disorders.

Keywords

GABA
GABAAR
Benzodiazepine
Barbiturates
Allosteric modulation
Autism spectrum disorder
Alzheimer’s disease
Epilepsy
Schizophrenia

Abbreviations

2-AG
2-Arachidonoylglycerol
AD
Alzheimer’s disease
AEA
Arachidonoylethanolamine
ASD
Autism spectrum disorder
Amyloid beta
BrdU
Bromodeoxyuridine
BZ/BZD
Benzodiazepine
CB
Cannabinoid receptors
CBD
Cannabidiol
CD
Cervical dystonia
DS2
Delta selective compound 2
f-MRI
Functional magnetic resonance imaging
GABA
γ-Aminobutyric acid
GABAARs
γ-Aminobutyric acid sub-type A receptors
GABA-T
GABA transaminase
GAD
Glutamic acid decarboxylase
GFAP
Glial fibrillary acidic protein
GPCRs
G protein-coupled receptors
ICD
Intracellular domain
LPI
Lysophosphatidylinositol
MRS
Magnetic resonance spectroscopy
MTG
Middle temporal gyrus
NADA
N-Arachidonoyl dopamine
NAM
Negative allosteric modulation
PAM
Positive allosteric modulation
PANSS
Positive and Negative Syndrome Scale
PET
Positron emission tomography
PFC
Prefrontal cortex
SAM
Silent allosteric modulators
SCAMP
Cysteine modification protection
SMEI
Severe myoclonic epilepsy in infancy
SSADH
Succinic semialdehyde dehydrogenase
SVZ
Subventricular zone
THC
Tetrahydrocannabinol
TMD
Transmembrane domains

Cited by (0)